Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Lucy Lu, insider at Veru

Lucy Lu Insider Information

Director of Veru
Lucy Lu, M.D. rejoins the Veru Board in May 2021 after previously serving as a Director of the Company from 2016 to 2019. Dr. Lu is the President and Chief Executive Officer of Avenue Therapeutics, Inc. From 2012 to 2017, Dr. Lu was the Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From 2007 to 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee’s College of Arts and Science.

What is Lucy Lu's net worth?

The estimated net worth of Lucy Lu is at least $66,900.00 as of May 11th, 2017. Dr. Lu owns 5,000 shares of Veru stock worth more than $66,900 as of May 22nd. This net worth estimate does not reflect any other investments that Dr. Lu may own. Learn More about Lucy Lu's net worth.

How do I contact Lucy Lu?

The corporate mailing address for Dr. Lu and other Veru executives is 48 NW 25th Street Suite 102, Miami FL, 33127. Veru can also be reached via phone at (305) 509-6897 and via email at [email protected] Learn More on Lucy Lu's contact information.

Has Lucy Lu been buying or selling shares of Veru?

Lucy Lu has not been actively trading shares of Veru over the course of the past ninety days. As far as recent transactions, 0 shares of the company's stock in a transaction on Sunday, May 22nd. Learn More on Lucy Lu's trading history.

Who are Veru's active insiders?

Veru's insider roster includes Harry Fisch (Director), and Lucy Lu (Director). Learn More on Veru's active insiders.

Are insiders buying or selling shares of Veru?

During the last year, Veru insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $32,544.00. During the last year, insiders at the sold shares 1 times. They sold a total of 100,000 shares worth more than $835,000.00. The most recent insider tranaction occured on August, 17th when Director Lucy Lu bought 4,800 shares worth more than $32,544.00. Insiders at Veru own 23.1 % of the company. Learn More about insider trades at Veru.

Information on this page was last updated on 8/17/2021.

Lucy Lu Insider Trading History at Veru

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2021Buy4,800$6.78$32,544.00View SEC Filing Icon  
5/11/2017Buy5,000$1.00$5,000.005,000View SEC Filing Icon  
See Full Table

Lucy Lu Buying and Selling Activity at Veru

This chart shows Lucy Lu's buying and selling at Veru by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veru Company Overview

Veru logo
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $13.38
Low: $12.66
High: $14.21

50 Day Range

MA: $9.08
Low: $4.35
High: $15.60

2 Week Range

Now: $13.38
Low: $4.34
High: $17.50


11,547,512 shs

Average Volume

24,788,880 shs

Market Capitalization

$1.07 billion

P/E Ratio


Dividend Yield



How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.